GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Wiley  (14)
  • 2020-2024  (14)
  • 1
    Online Resource
    Online Resource
    Ten‐year clinical outcomes from a randomized trial comparing new‐generation everolimus‐eluting stent versus first‐generation Sirolimus‐eluting stent: Results from the RESET extended study
    Wiley ; 2023
    In:  Catheterization and Cardiovascular Interventions Vol. 102, No. 4 ( 2023-10), p. 594-607
    Details
    In: Catheterization and Cardiovascular Interventions, Wiley, Vol. 102, No. 4 ( 2023-10), p. 594-607
    Abstract: New‐generation drug‐eluting stents (DES) achieved technological innovations and reported clinical advantages as compared with first‐generation DES in clinical trials with 3–5 years follow‐up. However, detailed clinical outcome data in very long‐term follow‐up is still scarce. Objectives To evaluate 10‐year clinical outcomes after first‐ and new‐generation DES implantation. Methods In this extende follow‐up study of the RESET, which is a largest randomized trial comparing everolimus‐eluting stent (EES) with Sirolimus‐eluting stent (SES), the study population consisted of 2892 patients from 84 centers. The primary efficacy and safety endpoints were target lesion revascularization (TLR) and a composite of death or myocardial infarction (MI), respectively. Complete 10‐year follow‐up was achieved in 87.9% of patients. Results Cumulative 10‐year incidences of TLR and non‐TLR were not significantly different between EES and SES (13.9% vs. 15.7%, Log‐rank p  = 0.20, and 33.4% vs. 31.3%, Log‐rank p  = 0.30). The cumulative 10‐year incidence of death/MI was also not significantly different between the groups (32.5% vs. 34.4%, Log‐rank p  = 0.18). Cumulative 10‐year incidence of definite stent thrombosis was numerically lower in EES than in SES (1.0% vs. 1.7%, Log‐rank p  = 0.16). The lower risk of EES relative to SES was significant for a composite endpoint of target lesion failure (TLF: 19.6% vs. 24.9%, Log‐rank p  = 0.001) and target vessel failure (TVF: 26.7% vs. 31.4%, Log‐rank p  = 0.006). Conclusion During 10‐year of follow‐up, the risks for primary efficacy and safety endpoints were not significantly different between new‐generation EES and first‐generation SES, although EES compared with SES was associated with a lower risk for composite endpoints such as TLF and TVF.
    Type of Medium: Online Resource
    ISSN: 1522-1946 , 1522-726X
    URL: Issue
    URL: Article
    DOI: 10.1002/ccd.v102.4
    DOI: 10.1002/ccd.30791
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2001555-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Prognostic significance of the HFA‐PEFF score in patients with heart failure with preserved ejection fraction
    Wiley ; 2021
    In:  ESC Heart Failure Vol. 8, No. 3 ( 2021-06), p. 2154-2164
    Details
    In: ESC Heart Failure, Wiley, Vol. 8, No. 3 ( 2021-06), p. 2154-2164
    Abstract: The HFA‐PEFF score is a part of the stepwise diagnostic algorithm of heart failure with preserved ejection fraction (HFpEF). We aimed to evaluate the prognostic significance of the HFA‐PEFF score on the clinical outcomes in patients with HFpEF. Methods and results The Prospective mUlticenteR obServational stUdy of patIenTs with Heart Failure with preserved Ejection Fraction (PURSUIT‐HFpEF) study is a prospective, multicentre, observational study in which collaborating hospitals in Osaka record clinical, echocardiographic, and outcome data of patients with acute decompensated heart failure with preserved left ventricular ejection fraction (≥50%) [UMIN‐CTR ID: UMIN000021831]. Acute decompensated heart failure was diagnosed on the basis of the following criteria: (i) clinical symptoms and signs according to the Framingham Heart Study criteria; and (ii) serum N‐terminal pro‐B‐type natriuretic peptide level of ≥400 pg/mL or brain natriuretic peptide level of ≥100 pg/mL. The HFA‐PEFF score has functional, morphological, and biomarker domains. We evaluated the prognostic significance of the HFA‐PEFF score (calculated based on the data at hospital discharge) on post‐discharge clinical outcomes in this cohort. The primary endpoint of the present study was a composite of all‐cause death and heart failure readmission. Between June 2016 and December 2019, 871 patients were enrolled from 26 hospitals (mean follow‐up duration 399 ± 349 days). A total of 804 patients were finally analysed after excluding patients with scores of 0 ( N  = 5) and 1 ( N  = 15) from 824 patients with available HFA‐PEFF score based on the echocardiographic and laboratory data at discharge. According to the laboratory and echocardiographic data at the time of discharge, 487 patients (59.1%) were diagnosed as HFpEF (HFA‐PEFF score ≥ 5) while 317 patients (38.5%) had intermediate score. Kaplan–Meier analysis divided by the HFA‐PEFF score [low, score 2–5 ( N  = 494) vs. high, score 6 ( N  = 310)] indicated that the HFA‐PEFF score successfully stratified the patients for the primary endpoint (log‐rank test P   〈  0.001). Cox proportional hazard model showed that the HFA‐PEFF score was significantly associated with the primary endpoint (high score with reference to low score, adjusted hazard ratio 1.446, 95% confidence interval [1.099–1.902], P  = 0.008). Conclusion The HFA‐PEFF score at discharge was significantly associated with the post‐discharge clinical outcomes in acute decompensated heart failure patients with preserved ejection fraction. This study suggested clinical usefulness of the HFA‐PEFF score not only as a diagnostic tool but also a practical prognostic tool.
    Type of Medium: Online Resource
    ISSN: 2055-5822 , 2055-5822
    URL: Issue
    URL: Article
    DOI: 10.1002/ehf2.v8.3
    DOI: 10.1002/ehf2.13302
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2814355-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
    Wiley ; 2021
    In:  Respirology Case Reports Vol. 9, No. 7 ( 2021-07)
    Details
    In: Respirology Case Reports, Wiley, Vol. 9, No. 7 ( 2021-07)
    Abstract: Unlike cytotoxicity, haematological toxicity is a rare immune‐related adverse event that is occasionally irreversible and refractory. A 67‐year‐old man was diagnosed with advanced lung squamous cell carcinoma. After 41 cycles of nivolumab as third‐line chemotherapy, the patient developed severe neutropenia and thrombocytopenia. The bone marrow biopsy and serum immunological tests indicated no evidence of bone marrow failure and suggested autoimmune mature blood cell destruction. After initiating treatment with prednisolone 50 mg orally and filgrastim 75 μg subcutaneously once daily, neutropenia and thrombocytopenia recovered within four and nine days, respectively. The filgrastim was discontinued four days later, and the corticosteroid was discontinued three months later; there has been no haemocytopenia recurrence since then. The patient has remained untreated for more than two years without progression of lung cancer. In conclusion, corticosteroids should be considered for the treatment of autoimmune haemocytopenia if refractory bone marrow dysplasia can be ruled out.
    Type of Medium: Online Resource
    ISSN: 2051-3380 , 2051-3380
    URL: Issue
    URL: Article
    DOI: 10.1002/rcr2.v9.7
    DOI: 10.1002/rcr2.799
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2750180-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study
    Wiley ; 2022
    In:  Geriatrics & Gerontology International Vol. 22, No. 4 ( 2022-04), p. 298-304
    Details
    In: Geriatrics & Gerontology International, Wiley, Vol. 22, No. 4 ( 2022-04), p. 298-304
    Abstract: We carried out a randomized controlled trial using ipragliflozin. We analyzed changes in diastolic function using echocardiography in patients with type 2 diabetes and heart failure with preserved ejection fraction. Methods We carried out an open‐label, multicenter, randomized, two‐arm interventional trial. A total of eligible 68 participants were randomly assigned into two groups (ipragliflozin group n  = 36; conventional treatment group n  = 32). Primary end‐points were the change in E / e ' and e '. Secondary end‐points were other parameters of echocardiography, plasma NT‐proBNP level, New York Heart Association class, hemoglobin A1c and blood pressure. Results After 24 weeks of follow up, E / e ' decreased in both groups (ipragliflozin: 11.0 vs 10.4; conventional treatment 10.5 vs 10.1; multivariate‐adjusted P  = 0.95). There were no significant differences in the amount of change in E / e ', e ', echocardiography parameters, plasma NT‐proBNP level, New York Heart Association class, hemoglobin A1c and blood pressure between the two groups. In the subgroup analysis, ipragliflozin treatment decreased in left ventricular mass index in patients aged ≥70 years and also decreased in NT‐proBNP levels in patients with baseline NT‐proBNP ≥400 pg/mL. Conclusions In this randomized controlled study carried out in patients with type 2 diabetes and heart failure with preserved ejection fraction, 24‐week ipragliflozin treatment did not improve left ventricular diastolic function compared with conventional treatment. As the subgroup, ipragliflozin treatment decreased in left ventricular mass index in participants aged ≥70 years. Geriatr Gerontol Int 2022; 22: 298–304 .
    Type of Medium: Online Resource
    ISSN: 1444-1586 , 1447-0594
    URL: Issue
    URL: Article
    DOI: 10.1111/ggi.v22.4
    DOI: 10.1111/ggi.14363
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2078308-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
    Wiley ; 2021
    In:  Thoracic Cancer Vol. 12, No. 22 ( 2021-11), p. 3062-3067
    Details
    In: Thoracic Cancer, Wiley, Vol. 12, No. 22 ( 2021-11), p. 3062-3067
    Abstract: In advanced lung cancer treatment, immunotherapy provides durable responses in some patients. However, other patients experience progressive disease and the resistance mechanisms to immunotherapy have yet been fully elucidated. Small cell transformation of non‐small cell lung cancer (NSCLC) is commonly recognized as one of the resistance mechanisms to epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors in EGFR ‐mutant NSCLC treatment. As a resistant mechanism for immunotherapy, we report the first case of small cell transformation in 2017. Since then, eight similar cases have been reported and the concept of small cell transformation is now becoming more prevalent as a mechanism of immunotherapy resistance. In our facility, we have experienced four cases of small cell transformation after immunotherapy (including the reported case in 2017). The histology of each primary tumor was squamous cell carcinoma, large cell type neuroendocrine carcinoma, or poorly differentiated NSCLC. None had driver gene mutations. Nivolumab was administered in all four cases and atezolizumab was administered as a next line to nivolumab treatment in one case. The best response to immunotherapy was partial response or stable disease. There was a wide range of periods from the start of immunotherapy to confirmation of small cell transformation (from 2 weeks to almost 3 years). In conclusion, small cell transformation is an important resistance mechanism in cancer immunotherapy. When NSCLC progresses after immunotherapy, the possibility of small cell transformation and rebiopsy should always be encouraged, as it leads to clarification of the resistance mechanisms and frequency.
    Type of Medium: Online Resource
    ISSN: 1759-7706 , 1759-7714
    URL: Issue
    URL: Article
    DOI: 10.1111/tca.v12.22
    DOI: 10.1111/1759-7714.14180
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2559245-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Exploring the contributing factors to multiple chemical sensitivity in patients with migraine
    Wiley ; 2022
    In:  Journal of Occupational Health Vol. 64, No. 1 ( 2022-01)
    Details
    In: Journal of Occupational Health, Wiley, Vol. 64, No. 1 ( 2022-01)
    Abstract: Multiple chemical sensitivity (MCS) is a form of chemical intolerance in which various systemic symptoms are triggered by exposure to a variety of chemical substances. Although migraine has been associated with central sensitivity syndrome, the relationship between MCS and migraine has not been studied. We assessed the frequency of MCS and its related factors in patients with migraine. Methods We performed a cross‐sectional study that included 95 patients (14 M/81 F; age, 45.4 ± 12.4 years) out of 100 consecutive patients with migraine from our outpatient headache clinic. MCS was defined as having a combination of Q1 ≥ 30, Q3 ≥ 13, and Q5 ≥ 17 on the quick environment exposure sensitivity inventory (QEESI; Japanese version). Central sensitization inventory‐A scores 〉 40 were considered an indication of central sensitization. Headache‐related disability and psychological distress were evaluated with the Migraine Disability Assessment score (MIDAS) and Kessler Psychological Distress Scale (K6), respectively. Results MCS was identified in 20% of patients with migraine; however, none had previously been diagnosed with MCS. The MCS‐positive group had higher rates of photophobia, osmophobia, visual aura, sensory aura, and central sensitization and higher MIDAS and K6 scores than the MCS‐negative group. A logistic regression analysis showed that osmophobia, sensory aura, and central sensitization were significant contributors to MCS. Conclusion We showed that MCS was observed in 20% of patients with migraine, and our study results may indicate a possible association of MCS with central sensitization and hypersensitivity‐related symptoms in patients with migraine.
    Type of Medium: Online Resource
    ISSN: 1341-9145 , 1348-9585
    URL: Article
    DOI: 10.1002/1348-9585.12328
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 1340985-2
    detail.hit.zdb_id: 2075956-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Efficacy and safety of immune checkpoint inhibitors in patients with non‐small cell lung cancer aged 80 years or older
    Wiley ; 2021
    In:  Cancer Reports Vol. 4, No. 6 ( 2021-12)
    Details
    In: Cancer Reports, Wiley, Vol. 4, No. 6 ( 2021-12)
    Abstract: In Japan, over 25% of the population is elderly. As the risk of lung cancer increases with age, the number of elderly patients with lung cancer also increases. Given the challenges of an aging society, it is critical that elderly patients receive safe therapies. Aim We assessed the safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with non‐small cell lung cancer (NSCLC) aged ≥80 years. Methods We retrospectively reviewed NSCLC patients aged ≥80 years old who received ICIs in the National Hospital Organization Kyoto Medical Center. We collected data on patient characteristics, prior treatments, number of cycles, response, and immune‐related adverse events (irAEs) during ICI monotherapy. Results A total of 45 patients were reviewed. The patients' median age was 85 years. Twenty‐one, 17, and 7 patients received nivolumab, pembrolizumab, and atezolizumab, respectively. The disease control rate (partial response [PR] + stable disease [SD] ) was 60.0%, and the progression‐free survival was 3.4 months. In patients with nivolumab, seven patients (33.3%) achieved SD, and three patients (14.2%) achieved PR. In patients treated with pembrolizumab, seven patients (41.2%) achieved SD, and six patients (35.3%) achieved PR. In patients with atezolizumab, three patients (42.9%) achieved SD, and one patient (14.2%) achieved PR. Sixteen (36%) patients presented with a poor performance status. Three patients treated with pembrolizumab experienced grade 3 pneumonia, while one patient treated with nivolumab experienced grade 5 pneumonia. Conclusion This study suggested that ICIs are an acceptable treatment option for NSCLC patients aged ≥80 years. Oncologists should pay attention to severe irAEs.
    Type of Medium: Online Resource
    ISSN: 2573-8348 , 2573-8348
    URL: Issue
    URL: Article
    DOI: 10.1002/cnr2.v4.6
    DOI: 10.1002/cnr2.1405
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2920367-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Obesity predicts persistence of resistant hypertension after surgery in patients with primary aldosteronism
    Wiley ; 2020
    In:  Clinical Endocrinology Vol. 93, No. 3 ( 2020-09), p. 229-237
    Details
    In: Clinical Endocrinology, Wiley, Vol. 93, No. 3 ( 2020-09), p. 229-237
    Abstract: Primary aldosteronism (PA) is considered a major cause of resistant hypertension (RHT). The prevalence of RHT has been recently reported to reach 18% in general hypertension. However, little is known about the prevalence and the outcomes after adrenalectomy of RHT in PA. Therefore, we aimed to clarify the prevalence and surgical outcomes in patients with both PA and RHT. Patients and Design Among 550 patients who underwent adrenalectomy for unilateral PA in the Japan PA Study, RHT was defined as an uncontrolled blood pressure (≥140/90 mm Hg) despite treatment with at least any three antihypertensives or hypertension controlled with at least four drugs. Surgical outcome was assessed by the biochemical and clinical outcome. Results Although 40 (7.3%) patients fulfilled the criteria for preoperative RHT, this should be underestimated because only 36% of patients with postoperative RHT were classified as having preoperative RHT. The prevalence of preoperative RHT was approximately 20% when estimated using the total number of patients with postoperative RHT and the ratio of postoperative RHT in patients with preoperative RHT. Although an improvement in hypertension was achieved in approximately 80% of patients with preoperative RHT, 20% of these exhibited persistent RHT. These patients were more obese than those for whom RHT improved after surgery. Notably, body mass index of ≥25 kg/m 2 was an independent predictor of postoperative RHT. Conclusions The prevalence of RHT in PA was lower than expected even with the adjustment for underestimation. Furthermore, obesity is an independent factor predicting the postoperative persistence of RHT.
    Type of Medium: Online Resource
    ISSN: 0300-0664 , 1365-2265
    URL: Issue
    URL: Article
    DOI: 10.1111/cen.v93.3
    DOI: 10.1111/cen.14203
    RVK:
    XA 10000
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2004597-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Single‐center analysis of antiresorptive agent‐related osteonecrosis of the jaw in lung cancer patients
    Wiley ; 2020
    In:  Asia-Pacific Journal of Clinical Oncology Vol. 16, No. 6 ( 2020-12), p. 380-384
    Details
    In: Asia-Pacific Journal of Clinical Oncology, Wiley, Vol. 16, No. 6 ( 2020-12), p. 380-384
    Abstract: Over the past two decades, antiresorptive agent‐related osteonecrosis of the jaw (ARONJ) has become a growing concern. We examined the incidence of ARONJ and identified its risk factors in lung cancer patients in the real‐world clinical setting. To our knowledge, we are the first to do so. Patients and methods We retrospectively analyzed lung cancer patients with bone metastases who had received anti‐resorptive agents (zoledronate or denosumab) at the National Hospital Organization Kyoto Medical Center from October 2012 to September 2018. All ARONJ cases were diagnosed by the dentists according to the established diagnostic criteria. Results A total of 171 patients were reviewed, 13 (7.6%) of whom experienced ARONJ. Among the 13 patients, six (46.2%), four (30.8%) and three (23.1%) had adenocarcinoma, squamous carcinoma and not otherwise specified, respectively. ARONJ was stage 2 in three (23.1%) patients and stage 3 in 10 (76.9%). More cycles of antiresorptive agents (odds ratio [OR] = 11.54; 95% confidence interval [CI] , 2.47–53.99; P   〈  0.01), use of immune checkpoint inhibitors (ICIs; OR = 5.05; 95% CI, 1.56–16.37; P   〈  0.01) and longer survival duration (≥2 years; OR = 12.16; 95% CI, 3.17–46.65; P   〈  0.01) were independently associated with ARONJ in a multivariate analysis. Conclusions The incidence of ARONJ was relatively high in lung cancer patients with bone metastases. When using antiresorptive agents, oncologists should closely monitor patients for ARONJ during the course of treatment and regularly consult with dentists, especially in patients receiving ICIs.
    Type of Medium: Online Resource
    ISSN: 1743-7555 , 1743-7563
    URL: Issue
    URL: Article
    DOI: 10.1111/ajco.v16.6
    DOI: 10.1111/ajco.13395
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2187409-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Successful correction of factor V deficiency of patient‐derived iPSCs by CRISPR/Cas9‐mediated gene editing
    Wiley ; 2020
    In:  Haemophilia Vol. 26, No. 5 ( 2020-09), p. 826-833
    Details
    In: Haemophilia, Wiley, Vol. 26, No. 5 ( 2020-09), p. 826-833
    Abstract: Factor V (FV) deficiency is a monogenic inherited coagulation disorder considered to be an ideal indication for gene therapy. To investigate the possibility of therapeutic application of genome editing, we generated induced pluripotent stem cells (iPSCs) from a FV‐deficient patient and repaired the mutation of factor V gene ( F5 ) using a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated 9 (Cas9). Methods The patient's peripheral blood mononuclear cells were reprogrammed for iPSCs. The targeting vector was designed with homology arms against F5 containing the corrected sequence. Cas9 ribonucleoprotein (RNP) complex and targeting vector were electroporated into iPSCs. Gene‐edited iPSCs were differentiated into hepatocyte‐like cells (HLCs). Results The mutation of F5 in patient‐derived iPSCs was repaired by CRISPR/Cas9. In concentrated culture supernatants of patient‐derived iPS‐HLCs, neither FV antigen nor activity was detected, while in those of gene‐corrected iPS‐HLCs, FV antigen and specific activity were 67.0 ± 13.1 ng/mL and 173.2 ± 41.1 U/mg, respectively. Conclusions We successfully repaired the mutation of F5 using the CRISPR/Cas9 and confirmed the recovery of FV activity with gene‐corrected iPS‐HLCs. Gene‐edited iPSCs are promising for elucidating the pathophysiology as well as for a modality of gene therapy.
    Type of Medium: Online Resource
    ISSN: 1351-8216 , 1365-2516
    URL: Issue
    URL: Article
    DOI: 10.1111/hae.v26.5
    DOI: 10.1111/hae.14104
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2006344-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...